ABSTRACT
This chapter describes the role of angiogenesis in malignancy and discusses the small molecule inhibitors currently under clinical investigations. It discusses the role of antibodies and other novel agents in the treatment of lung cancer. Angiogenesis is vital for tumor growth. High levels of angiogenesis mediators inversely correlate with outcomes in lung cancer. Inhibition of angiogenesis is associated with suppression of tumor growth and increased delivery of chemotherapeutic drugs and hence with improved outcomes. Baseline levels of intercellular adhesion molecule (ICAM) and vascular endothelial growth factor (VEGF) appear to predict outcomes in response to bevacizumab. Confirmation of these associations in prospective studies may help to identify those who may benefit the most with antiangiogenic therapy. Future studies will evaluate the role of several angiogenesis inhibitors as single agents and in combination with chemotherapy and other targeted agents.
